Unbound MEDLINE

A Clinical Algorithm Identifies High Risk Pediatric Oncology and Bone Marrow Transplant Patients Likely to Benefit From Treatment of Adenoviral Infection. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology [J Pediatr Hematol Oncol] Journal article

 
TitleA Clinical Algorithm Identifies High Risk Pediatric Oncology and Bone Marrow Transplant Patients Likely to Benefit From Treatment of Adenoviral Infection.
Author(s)Williams KM, Agwu AL, Dabb AA, Higman MA, Loeb DM, Valsamakis A, Chen AR 
InstitutionDepartments of *Oncology daggerPediatrics double daggerInfectious Diseases section signPharmacy parallelPathology, Johns Hopkins University, Baltimore, MD.
SourceJ Pediatr Hematol Oncol 2009 Oct 1.
AbstractBACKGROUND: Adenoviral infections cause morbidity and mortality in blood and marrow transplantation and pediatric oncology patients. Cidofovir is active against adenovirus, but must be used judiciously because of its nephrotoxicity and unclear indications. Therefore, before introducing cidofovir use during an adenoviral outbreak, we developed a clinical algorithm to distinguish low risk patients from those who merited cidofovir therapy because of significant adenoviral disease and high risk for death.
OBJECTIVE: This study was conducted to determine whether the algorithm accurately predicted severe adenovirus disease and whether selective cidofovir treatment was beneficial.
STUDY DESIGN: A retrospective analysis of a pediatric oncology/blood and marrow transplantation cohort prealgorithm and postalgorithm implementation was performed.
RESULTS: Twenty patients with adenovirus infection were identified (14 high risk and 6 low risk). All low-risk patients cleared their infections without treatment. Before algorithm implementation, all untreated high-risk patients died, 4 out of 5 (80%), from adenoviral infection. In contrast, cidofovir reduced adenovirus-related mortality in the high-risk group postalgorithm implementation (9 patients treated, 1 patient died; RR 0.14, P<0.05) and all treated high-risk patients cleared their virus.
CONCLUSIONS: The clinical algorithm accurately identified patients at high risk for severe fatal adenoviral disease who would benefit from selective use of cidofovir.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19801951
  
Advertise on this site.